Supernus Pharmaceuticals
Launch date
Employees
Market cap
€1.6b
Enterprise valuation
€1.3b (Public information from Sep 2024)
Share price
$32.13 SUPN
Rockville Maryland (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 520m | 580m | 667m | 608m | 622m | 626m | 691m |
% growth | 32 % | 11 % | 15 % | (9 %) | 2 % | 1 % | 10 % |
EBITDA | 210m | 120m | 150m | 109m | 127m | 111m | 157m |
% EBITDA margin | 40 % | 21 % | 22 % | 18 % | 20 % | 18 % | 23 % |
Profit | 127m | 53.4m | 60.7m | 1.3m | 15.9m | (49.4m) | 38.4m |
% profit margin | 24 % | 9 % | 9 % | - | 3 % | (8 %) | 6 % |
EV / revenue | 2.5x | 2.7x | 2.9x | 2.6x | 3.1x | 3.1x | 2.8x |
EV / EBITDA | 6.3x | 12.9x | 12.9x | 14.5x | 15.3x | 17.5x | 12.4x |
R&D budget | 76.0m | 90.5m | 74.6m | 91.6m | - | - | - |
R&D % of revenue | 15 % | 16 % | 11 % | 15 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$17.5m | Series A | ||
N/A | $30.0m | Debt | |
N/A | $42.0m | Growth Equity VC | |
N/A | N/A | IPO | |
* | N/A | $90.0m | Post IPO Debt |
* | N/A | $350m | Post IPO Debt |
* | $150m | Post IPO Debt | |
Total Funding | €54.1m |
Recent News about Supernus Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Supernus Pharmaceuticals
EditACQUISITION by Supernus Pharmaceuticals Oct 2021
ACQUISITION by Supernus Pharmaceuticals Sep 2018